ICU patients may need different antifungal doses, study finds
NCT ID NCT02164890
Summary
This study examined how the antifungal drug micafungin behaves in critically ill patients. Researchers measured drug levels in 60 intensive care patients with serious fungal infections to see if standard doses provide enough medication. The goal was to understand if these vulnerable patients might need personalized dosing for better treatment outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASIVE CANDIDIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Montpellier
Montpellier, 34295, France
Conditions
Explore the condition pages connected to this study.